ReviewACS biomaterials science & engineering2025
Engineering Schottky Junction Nanocatalysts for Enhanced Charge Carrier Separation and Synergistic PDT/PTT/CDT in Bladder Cancer Therapy.
Review in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- 2D nanomaterials for near infrared responsive photomedicine: a review.Nano convergence · 2026Review
- Application of multimodal nanotechnology and standardized nursing management in ventricular arrhythmia.Biomedical engineering online · 2026Review
- Harnessing a cRGD-Targeted Schottky Junction MXene Nanocomposite for Potent Bladder Cancer Therapy: Dual-Modal PTT/PDT Effects with Immune Activation and Favorable Comparison to Doxorubicin.International journal of nanomedicine · 2026Article
- Application and challenges of smart responsive multifunctional nanoplatforms in integrated diagnosis and treatment of bladder cancer and overcoming therapeutic resistance.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is one of the most prevalent malignancies of the urinary system and poses significant therapeutic challenges, including high recurrence rates, drug resistance, and treatment-related side effects. In recent years, Schottky junction nanocatalysts have attracted considerable attention in the field of oncology due to their enhanced light-driven electrodynamic properties and promising therapeutic potential. This review provided a comprehensive overview of the underlying mechanisms of Schottky junction nanocatalysts and their core advantages. Moreover, the application of nanomaterials in multimodal therapy for bladder cancer was further elaborated, including photothermal therapy (PTT), photodynamic therapy (PDT), and synergistic chemodynamic therapy. By analyzing the latest advances in preclinical research, we highlighted the role of these nanocatalysts in enhancing therapeutic efficacy, minimizing systemic toxicity, and improving patient survival outcomes. Simultaneously, it outlines the present issues with nanomaterials and the clinical barriers impeding their widespread adoption. These findings offer valuable insights into the future clinical translation of nanotechnology-based treatments for bladder cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.